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doi:10.1016/j.jmii.2012.03.009Background: The combination of fusidic acid and rifampicin has a demonstrated synergistic
effect against methicillin-resistant Staphylococcus aureus (MRSA), including planktonic and
biofilm-related organisms. However, the in vitro efficacy of other combinations of oral anti-
MRSA antibiotics in biofilm models has not been established.
Methods: The antibacterial activity of fusidic acid, linezolid, rifampicin, and minocycline
against 33 biofilm-embedded MRSA isolates in low susceptibility and high resistance breakpoint
concentrations was investigated using the 3-[4, 5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2H-tetra-
zolium-bromide staining method. The compounds were further examined to determine their
antibacterial efficacies in combination. The optical density ratio (ODr) was used to evaluate
the antibacterial effects of these antibiotics, and the results indicate higher survival rates
of MRSA on biofilm. A biofilm-positive phenotype (determined using the crystal violet stain)
was defined as an optical density  0.17 at 492 nm, and strong biofilm formation was defined
as an optical density  1.0.of Medical Research, Chi Mei Medical Center, Number 901 Chung-Hwa Road, Yung-Kang City 710,
t of Internal Medicine, National Cheng Kung University Hospital, Number 138, Sheng Li Road, 704
ail.com (W.-C. Ko), 8409d1@gmail.com (H.-J. Tang).
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90 W.-S. Wu et al.Results: One-third of the MRSA isolates demonstrated weak biofilm formation, and two-thirds
demonstrated strong biofilm formation. At low concentrations, linezolid alone lowered the ODr
to 0.55 and was effective against biofilm-embedded MRSA (p< 0.001). The activity of minocy-
cline was concentration-dependent and more effective against MRSA isolates that demon-
strated weak biofilm formation. The effect of minocycline seems to be further enhanced
when used in combination with either fusidic acid or linezolid at low concentrations, with
the obtained results equal to those obtained with rifampicin-based regimens (p< 0.001).
Rifampicin plus minocycline was also effective against MRSA in biofilm.
Conclusion: In comparison with monotherapy, minocycline-based combinations exhibit highly
effective bactericidal effects against biofilm-embedded MRSA.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) causes
a variety of infections, including bacteremia, septic
arthritis, osteomyelitis, and artificial graft infections such
as those that occur in artificial joints.1e3 When infected
artificial grafts are retained, biofilm-associated infections
are very difficult to treat.4 Consequently, long-term
combination oral antibiotic therapies are needed that not
only effectively treat biofilm-related infections but also
demonstrate few side effects. Some in vitro studies on the
antibacterial effects of combination therapies have been
performed on biofilms.4e12 Among these, rifampicin has
a demonstrated synergistic effect against MRSA, including
planktonic and biofilm-related organisms.3,11,13 In a review
of the literature, it was found that minocycline alone is
highly activedeven more effective than other anti-MRSA
antibioticsdagainst biofilm-embedded MRSA isolates.14,15
Considering the hepatotoxicity of rifampicin,16 the devel-
opment of a minocycline-based combination therapy (such
as those that incorporate fusidic acid or linezolid) may be
especially important for overcoming the present problem of
treating biofilm-associated MRSA infections that require
long-term oral antibiotics. In this in vitro study, we exam-
ined the efficacy of minocycline, in combination with other
available oral anti-MRSA agents, for reducing the bacterial
burden on biofilms.Materials and methods
Bacterial isolates
Thirty-three MRSA isolates, including those from blood
(nZ 18), joint fluid (nZ 7), pus (nZ 5), and other aseptic
specimens (nZ 3), were randomly obtained from patients
with clinical infections from the clinical microbiology
laboratory of Chi-Mei Foundational Hospital (Tainan,
Taiwan). Staphylococcus species were identified by colonial
morphology, Gram staining, and coagulase testing. MRSA
was further confirmed by tube coagulase testing and growth
on a 6 mg/mL oxacillin salt-agar screening plate. The
organism was stored at e70C in Protect Bacterial
Preservers (Technical Service Consultants Limited, Hey-
wood, Lancashire, England) before use.Antibiotics and minimum inhibitory concentrations
The antibiotics that were tested included rifampicin and
minocycline (Sigma, St. Louis, MO, USA), linezolid (Pfizer,
New York, NY, USA), and fusidic acid (Leo, Ballemp,
Denmark). The minimum inhibitory concentrations (MICs)
were determined by agar dilution, according to the recom-
mendations from the Clinical and Laboratory Standards
Institute (CLSI).17 Interpretation criteria for susceptibility
testing were based on the guidelines from CLSI or the British
Society for Antimicrobial Chemotherapy (BSAC).17,18 The
inoculum was 5.0 105 colony-forming units (CFU)/mL. The
inoculated plates were incubated in ambient air at 37C for
24 hours. The MIC was defined as the lowest concentration
of antibiotic that yielded no visible growth after overnight
incubation. S. aureus ATCC 29213 was included in each run
as the standard quality control strain.
Biofilm formation
Isolates were cultured for 1 day at 37C in 5 mL of tryptic
soy broth that was supplemented with 1% D-glucose
(TSBGlc). The cultures were diluted to 1:1000 in TSBGlc,
and 200 mL aliquots were added to each well of a 96-well
tissue culture-treated polystyrene plate. After 24 hours of
growth at 37C, the plates were vigorously washed three
times with phosphate-buffered saline (PBS) to remove any
unattached bacteria and then dried for 1 hour at 60C prior
to staining with 0.4% crystal violet solution. The optical
density (OD) was used as an index of bacterial adherence to
the surface and biofilm formation. Experiments were per-
formed in triplicate, the results were averaged, and stan-
dard deviations were calculated. To compensate for
background absorbance, OD readings of the sterile medium
with both the fixative and dye were averaged and sub-
tracted from all of the experimental values. A biofilm-
positive phenotype was defined as OD 0.17 at 492 nm
(OD492). Strong biofilm formation was classified as
OD492 1.0, and weak biofilm formation was classified as
OD492 between 0.17e1.0.
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Biofilm staining method
A 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium-
bromide (MTT) assay was performed using the method
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The MTT method can be used to evaluate the antibacterial
activities of different drugs in the biofilm model and has
been reported in the literature23e26 but not by CLSI. Briefly,
at the endpoint of the treatment of the biofilms with anti-
biotics, the wells were emptied and washed three times
with 200 mL of sterile PBS. Then, 100 mL PBS with 1% MTT
(Sigma) solution was added and allowed to incubate for 2
hours at 37C. The MTT solution was replaced with 100 mL
dimethyl sulfoxide and allowed to incubate for 15 minutes
at room temperature. Viable bacteria reduced the tetrazo-
lium salt to a purple water-soluble formazan product. The
numbers of surviving bacteria are determined before and
after a 90-minute incubation by measuring their ability to
reduce the yellow tetrazolium salt, 3-(4,5-dimethylthiazol-
2-yl)2,5-diphenyltetrazolium bromide (MTT) to a purple
formazan product. This reaction, which is mediated by
bacterial dehydrogenases, can be detected colorimetrically
by reading the plates on a microtiter plate reader at 570 nm.
Higher OD values indicate an increased number of surviving
MRSA isolates in the biofilm.
Minimum biofilm eradication concentration
The antibacterial activity of each drug in the biofilm was
measured using the minimum biofilm eradication concen-
tration (MBEC) assay.27 MBEC indicates the lowest concen-
trations of the antimicrobial agent leading to clear wells in
the 96-well ELISA platforms. The assay involved biofilm
formation on the plastic pegs of the lid of the MBEC device.
These biofilms were then exposed to the tested antibiotics
for a defined period of time in a 96-well plate and incu-
bated overnight. The MBEC value corresponds to the lowest
dilution that prevents the regrowth of bacteria on the
treated biofilm. This assay was validated in terms of
reproducibility and accuracy by the standard reference
isolates, according to the methods specified by CLSI.
MBEC50 and MBEC90 are the minimum concentrations that
inhibit 50% or 90% of the isolates from forming on the bio-
film, respectively.
Antimicrobial effects of the antimicrobial agents on
the biofilms
The biofilms of each isolate were prepared in two sepa-
rated 24-well culture plates, as described above. The
medium-free biofilm on the plate was incubated with fusi-
dic acid, linezolid, rifampicin, and minocycline (either
alone or in combination) for 1 day at 37C. The biofilm of the
wells in one plate was stained with MTT. The wells of the
other plates were refilled with fresh dilutions of antimicro-
bial agents every day for 5 consecutive days and then stained
with MTT. Two concentrations of antimicrobial agentsdthe
susceptibility and resistance breakpointsdwere used in
accordance with CLSI guidelines. Group 1 included antibi-
otics at low concentrations (fusidic acid: 1 mg/mL; linezolid:
4 mg/mL; rifampicin: 1 mg/mL; minocycline: 4 mg/mL), and
group 2 included antibiotics at high concentrations (fusidic
acid: 2 mg/mL; linezolid: 8 mg/mL; rifampicin: 4 mg/mL;
minocycline: 16 mg/mL). To account for the individual bio-
film formation of each isolate, the ratio of the biofilm OD ofthe isolate that was incubated with the antibiotics was
calculated in relation to the biofilm OD of the same isolate
without antibiotics (native biofilm). The baseline of the
untreated biofilm was set to 1. This optical density ratio
(ODr) was used to measure changes in the viable MRSA on
each biofilm. The average color intensity of soluble for-
mazan, including the effects of the single agents and the
combination therapies on the 33 MRSA isolates on the bio-
film, was compared with every control group on the fifth day
and is presented in terms of the ODr values. A lower ODr
indicates a greater inhibitory effect on the MRSA biofilm. All
experiments were performed in triplicate, and all studies
were repeated three times.
Colony counting
To count the number of colonies formed, 10 out of 33 MRSA
isolates were randomly selected. After the 5-day incuba-
tion period with the antibiotics, the biofilm-containing
wells were sonicated using a water table sonicator (VWR
International, model 250HT) for 5 minutes. The disrupted
biofilm was serially diluted, plated, and incubated over-
night at 37C for viable cell counting. The detection limit of
the plate counting method was 100 CFU/mL.
Statistical analysis
Data were recorded as the mean standard deviation.
Because of the small sample size and the abnormal distri-
bution of ODr values, the Mann-Whitney U test was used to
compare differences between the two groups, and the
Kruskal-Wallis H test followed by the Dunn’s test was used
for multiple comparison analysis. Statistical significance
was set to p< 0.05. The Bonferroni correction rule was
applied when multiple comparisons were performed. Data
were analyzed using SPSS 17.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
Of the 33 MRSA isolates, biofilm formation was weak in one-
third (11 isolates) of the isolates and strong in the
remaining two-thirds (22 isolates). The MIC and MBEC50/90
values of the different antibiotics against planktonic and
biofilm MRSA are shown in Table 1. Of the isolates studied,
only 39% of the planktonic isolates were susceptible to
minocycline, whereas 21% and 6% of the biofilm-embedded
isolates were susceptible to rifampicin and minocycline,
respectively. Moreover, for each drug there were no
significant differences in terms of the antibacterial activi-
ties against the antimicrobial-susceptible and -resistant
isolates that were embedded in the biofilms.
When each of the four antibiotics were used alone at
susceptibility breakpoint concentrations (SBCs) (Fig. 1),
linezolid was more effective against biofilm-embedded
MRSA (ODrZ 0.55) in comparison with the control group
(p< 0.001) When minocycline was used in a combination
with the other three antibiotics, the combination of all four
were also more effective than the control and reduced the
ODr to around 0.29 or 0.47 (p< 0.001). When used in
combination with rifampicin, fusidic acid, minocycline, and
Table 1 Antimicrobial susceptibilities, minimum inhibitory concentrations (MIC50/90), and minimum biofilm eradication
concentrations (MBEC50/90) of four antibiotics against 33 planktonic or biofilm-embedded MRSA isolates
Drugs Planktonic MRSA Biofilm-embedded MRSA
MIC50, mg/mL MIC90, mg/mL Susceptible, % MBEC50, mg/mL MBEC90, mg/mL Susceptible, %
Fusidic acid 0.12 4 88 8 > 256 0
Linezolid 2 2 100 64 > 256 0
Minocycline 8 16 39 16 64 6
Rifampicin < 0.06 < 0.06 100 8 > 256 21
92 W.-S. Wu et al.linezolid reduced the ODr to approximately 0.24e0.31,
yielding greater antimicrobial effects than the control
(p< 0.001). The minocycline- and rifampicin-based combi-
nation regimens also exhibited greater antimicrobial effect
over fusidic acid, linezolid, minocycline, and rifampicin
monotherapy (p< 0.05). One exception is that the combi-
nation of linezolid plus minocycline seems to be more
effective than minocycline alone. However, there was no
obvious statistical difference when compared with linezolid
alone because linezolid monotherapy is effective against
biofilm-embedded MRSA. Besides, there was no obvious
statistical difference (p> 0.05) between the given rifam-
picin- and minocycline-based combinations.
When the same antibiotics were used alone at resistance
breakpoint concentrations (RBCs) (Fig. 2), the antibacterial
effects of linezolid and minocycline were more apparent
(ODrZ 0.37 and 0.27, respectively) against biofilm-
embedded MRSA on the fifth day (p< 0.001) in compar-
ison with the control group. On the other hand, the ODr on
the fifth day was lower than the ODr on the first day for
linezolid and minocycline. However, the ODr gradually
increased from the first through the fifth days for rifampicinCO
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Figure 1. Optical density ratios (ODr) of the four antibiotics
used (either alone or in combination) to treat 33 MRSA isolates
in biofilm. The isolates were exposed to susceptibility break-
point concentrations of the following antibiotics for 5 days:
fusidic acid (FA), 1 mg/mL; linezolid (LNZ), 4 mg/mL; rifampicin
(RIF), 1 mg/mL; and minocycline (MNO), 4 mg/mL. The optical
density of MRSA growth on the biofilm, without treatment by
antibiotics, was used as the control. Data are shown as themean
values standard deviations. *Indicates a p value< 0.0001.and fusidic acid. Regarding the minocycline-based combi-
nation, all three antibiotics seemed to be more effective
than the control and reduced the ODr to approximately 0.18
or 0.23 (p< 0.001). The rifampicin-based combination also
seemed to be more effective than the control and reduced
the ODr to 0.18, 0.27, and 0.37 for minocycline, linezolid,
and fusidic acid, respectively (p< 0.001). Comparing the
antibacterial effects of the different concentrations of
antibiotics, the ODr of the RBC was generally lower than
the SBC (p< 0.05) of the minocycline-based group.
However, there was no significant difference in terms of the
antibacterial effects of the minocycline- and rifampicin-
based regimens at RBC on biofilm-embedded MRSA
(p> 0.05).
Regarding the antibacterial effects of the single and
combination regimens on the strong and weak biofilm-
forming groups (Fig. 3), minocycline decreased the ODr to
0.43 and seemed to be more effective against the weak
biofilm-forming MRSA group in comparison with the strong
biofilm-forming group (ODrZ 1.00) (p< 0.05). When fusidic
acid was added to minocycline, the ODr of the weak
biofilm-forming group was decreased to 0.25 in comparisonCO
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Figure 2. Optical density ratios (ODr) of the four antibiotics
used (either alone or in combination) to treat 33 MRSA isolates
in biofilm. The isolates were exposed to resistance breakpoint
concentrations of the following antibiotics for 5 days: fusidic
acid (FA), 2 mg/mL; linezolid (LNZ), 8 mg/mL; rifampicin (RIF),
4 mg/mL; andminocycline (MNO), 16 mg/mL. The optical density
of MRSA growth on the biofilm, without treatment by antibi-
otics, was used as the control. Data are shown as the mean
values standard deviations. *Indicates a p value< 0.0001.
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Figure 3. Comparisons of the antibacterial activities of the
four antibiotics used (either alone or in combination) to treat
MRSA isolates with strong and weak biofilm-forming groups.
These groups were exposed to susceptibility breakpoint
concentrations of the following drugs for 5 days: fusidic acid
(FA), 1 mg/mL; linezolid (LNZ), 4 mg/mL; rifampicin (RIF), 1 mg/
mL; and minocycline (MNO), 4 mg/mL. The optical density
ratios (ODr) are shown below and compared with the control
(defined as 1.0). Data are shown as the mean values standard
deviations. *Indicates a p value< 0.05.
Antimicrobial activity against MRSA on biofilms 93with the strong biofilm-forming group (ODrZ 0.05)
(p< 0.05).
We also wanted to compare the accuracies and differ-
ences between ODr and colony counting for measuring the
survival of MRSA on biofilms (Fig. 4). For colony counting, 10
of the 33 MRSA isolates were randomly selected, and 8 of
these 10 MRSA isolates were resistant to minocycline. UsingCon
trol FA LN
Z RIF
FA
+R
IF
LN
Z+R
IF
MN
O
FA
+M
NO
LN
Z+M
NO
RIF
+M
NO
lo
g 1
0C
FU
 
3
4
5
6
7
8
Figure 4. Antibacterial activities of the four antibiotics used
(either alone or in combination) to treat 10 MRSA isolates on
biofilm. These isolate were exposed to susceptibility break-
point concentrations of the following drugs for 5 days: fusidic
acid (FA), 1 mg/mL; linezolid (LNZ), 4 mg/mL; rifampicin (RIF),
1 mg/mL; and minocycline (MNO), 4 mg/mL. Colony counts are
shown as the means standard deviations.SBC and CFU counts instead of ODr to measure the survival
of MRSA on biofilm, linezolid was shown to decrease
the colony count by about 2 log10-fold by the fifth day
compared with the control group. Regarding the combina-
tion groups, minocycline- and rifampicin-based regimens all
demonstrated high antibacterial effects with no obvious
differences between them (p> 0.05). Minocycline plus
rifampicin decreased the colony count by approximately 4
log10-fold, which seems to be the most effective combina-
tion regimen, exhibiting an enhanced antibacterial effect
in contrast with monotherapy. The results of the two
methods are comparable and the correlation coefficient
was 0.86 (pZ 0.0014).Discussion
In this study, we evaluated the antibacterial effects of
combinations of oral antibiotics on 33 biofilm-embedded
MRSA isolates. Linezolid at SBC seemed to be effective.
Rifampicin was initially inhibitory, but there was bacterial
regrowth at two different concentrations (data not shown).
This result is comparable with that the results reported by
Raad et al,15 which showed that rifampicin initially causes
a significant decrease in MRSA colonization on biofilms.
However, after repeated daily exposure to rifampicin, most
of MRSA isolates develop resistance to this antibiotic.15
According to a previous study, rifampicin is a constituent
of all of the combinations that are active against MRSA and
is a part of any antibiotic therapy that is directed against
biofilms formed by these organisms.11 In our study, rifam-
picin plus linezolid was effective and demonstrated an
enhanced antibacterial effect compared with mono-
therapy. This result is comparable with those of a previous
study.15 Compared with the study by Aboltins et al,13 fusidic
acid plus rifampicin seems to be as effective as it was in our
biofilm model. Such a rifampicin-based regimen is useful
and critically important because oral formulations need to
be available for long-term therapy.
Our study demonstrates that minocycline plus linezolid
or fusidic acid at SBC is as effective as rifampicin-based
regimens and this combination, when applied at the higher
RBC, was even more effective, even in cases where 80% of
the MRSA isolates were resistant to minocycline. In our
model, a low concentration of minocycline alone was
ineffective. However, minocycline-based combinations
demonstrated enhanced antibacterial effects. The anti-
bacterial effect of minocycline in this study was not as
strong as that reported in a previous study,15 in which
minocycline exhibited a greater antibacterial effect than
linezolid did in the biofilm model. These discordant results
may be related to differences in the experimental meth-
odology between the two studies.
The antibacterial effect of minocycline seems to be
greater in the weak biofilm-forming group. However, the
effects of the other three antibiotics on both groups were
the same. Therefore, according to our results, the thick-
ness of the biofilm does not seem to be related to the
antibacterial effect, except in the case of minocycline.
Fusidic acid plus minocycline exhibited an obviously
enhanced antibacterial effect on the weak biofilm-forming
MRSA isolates. Clinically, we expect that the invasive MRSA
94 W.-S. Wu et al.biofilm intensity can be used to predict the success rate of
minocycline combination therapies.
Because high concentrations of antibiotics are necessary
to treat biofilm-related infections, according to the findings
published in the literature and our results,15 we must
prescribe higher doses of antibiotics to achieve effective
serum levels. However, high-dose antibiotics are not always
practical in vivo because high concentrations increase the
toxicity and introduce related side effects. According to our
results, low-concentration combination therapies that use
minocycline plus fusidic acid, linezolid, or even rifampicin
seem to effectively eradicate biofilm-related MRSA. The
combination of minocycline and either linezolid or fusidic
acid seems to be an alternative for patients who cannot
tolerate rifampicin.
Minocycline, when used in combination with either
fusidic acid, linezolid, or rifampicin, is a good choice for
clinicians because all of these antibiotics are available in
oral form. The role of minocycline is more important than
rifampicin, especially in patients with liver cirrhosis where
long-term treatment with rifampicin is intolerable. Long-
term use of linezolid may lead to bone marrow suppression.
In this situation, the role of fusidic acid plus minocycline
becomes relatively more important and useful, especially
for treating weak biofilm-forming MRSA.
Because the concentrations of different antibiotics in
the bones, synovial membranes, and joint spaces are vari-
able, and because in vitro study results cannot completely
explain or represent biofilm-related infections, further
in vivo and clinical investigations are required to verify the
potential advantage of minocycline when used in combi-
nation with other antistaphylococcal antibiotics to treat
biofilm-related infections.
In conclusion, we have described the significant anti-
bacterial activities of minocycline-based combination
regimens, i.e., minocycline in combination with either
fusidic acid, linezolid, or rifampicin, in a biofilm model of
MRSA infection. However, their clinical significance
requires further study.
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